●EP——the European Pharmacopoeia,欧洲药典 ●EDL——Essential Drugs List ,基本药物目录 ●RDL——Reimbursement Drug List,医保(报销药品)目录 05 生产 Manufacturing ●Chemistry, Manufacturing, and Controls (CMC):药品的化学、生产和控制 ●Active Pharmace...
The article focuses on the safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in relation to suicidal thoughts among older adults with type 2 diabetes, including the need for further investigation into the effects of these drugs on younger populations and the l...
For instance, it has been shown that anti-diabetic drugs counteracting insulin resistance (i.e. metformin) seem to decrease PDAC risk, whereas the ones aimed to circulating insulin enhancement (i.e. insulin analogs) manifest an increased risk [36,37,38,39]. Data on a novel class of anti-...
GLP-1 Pharma Weight loss drugs from Lilly, Novo may cut risk of Alzheimer's A study indicates that new weight loss drugs may reduce the risk of Alzheimer’s disease while increasing the risk of other disorders. Kevin DunleavyJan 21, 2025 2:45pm...
GLP-1是我们胃肠道内天然分泌的一种激素，在我们吃了东西后，通过促进胰岛素的分泌，来抑制高血糖素的...
Table 1. Comprehensive list of incretin receptor-targeting drugs for metabolic disease treatment. Numerous incretin receptor-targeting treatments have been approved (red if in the United States, green if abroad) or are currently in clinical trials or being developed (blue) for metabolic diseases, nam...
GLP-1的初始作用在胰岛的胰岛素分泌细胞中被观察到,在该处其刺激葡萄糖依赖的胰岛素分泌。之后,发现了GLP-1的多种另外的抗糖尿病作用,包括对胰β细胞生长的刺激和对其细胞凋亡的抑制(Drucker,D.J.,Endocrinology 144:5145-8(2003);Holz,G.G.和Chepurny O.G.,Curr.Med.Chem.10:2471-83(2003);List,J.F....
These are patients who are inadequately controlled by one or two anti-diabetic drugs. They are randomly divided into a 1:1 ratio. The first group of patients have received semaglutide 1 mg weekly and the other group has received 2 mg Exenatide extended-release once weekly. After ...
1 RA in eligible, at-risk patients. Targets could be set for increasing the proportion of such patients receiving cardiorenal protective glucose-lowering drugs over time, and physicians could be supported with individual feedback, such as suggesting switching to SGLT2i or GLP-1 RA in appropriate...
1. A combination comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist, wherein the FGF21 compound has an FGF21 activity which is the same or substantially the same as the FGF21 activity of native FGF21 and is an FGF21 varian...